SUMO (Small Ubiquitin-like Modifier) is a ubiquitin-like protein that can covalently modify a large number of cellular proteins. SUMOylation is a dynamic process that is mediated by activating (E1), conjugating (E2), and ligating (E3) enzymes and readily reversed by a family of SUMO-specific proteases (SENP). We showed that inactivation of the SENP1 gene causes embryonal lethality in mid- gestation in mice as a result of severe fetal anemia stemming from deficient erythropoietin (Epo) production. SENP1 controls Epo production by regulating the stability of hypoxia-inducible factor 11 (HIF11) in hypoxic condition. During normoxia, HIF11 is hydroxylated in two critical proline residues by a family of oxygen sensing enzymes. Proline hydroxylation is important for HIF11 to binds to its ubiquitin ligase complex, von Hippel-Lindau protein VHL/elongin B/C complex, leading to ubiquitination and proteasomal degradation. We showed that hypoxia induced rapid SUMOylation of HIF11, which allowed it to bind to VHL in a hydroxyl-proline-independent manner, also leading to ubiquitination and proteasomal degradation. SENP1 reverses SUMOylation of HIF11, reduces binding to VHL, and consequently stabilizes HIF11. Thus, SENP1 plays a critical role in regulating HIF11 stability during hypoxia. Since HIF11 regulates multiple, critical downstream genes, such as Epo and VEGF, it has the potential to regulate erythropoiesis and angiogenesis. In preliminary results, we showed that accumulation of SUMOylated HIF11 peaked at four hours after exposure to hypoxia and later declined. This corresponded to an early phase of SUMOylation, most likely by an increase in SUMO E3 activity and a later phase of de-SUMOylation, most likely mediated by an increase in SENP1 activity. In this proposal, we will examine the role of SUMOylation and de-SUMOylation in HIF11 regulation by hypoxia and its downstream effects, focusing on angiogenesis.
AIM 1 : To identify the E3 responsible for hypoxia-induced SUMOylation of HIF11.
AIM 2 : To study how SENP1 is regulated by hypoxia.
AIM3 : To determine whether SENP1 regulates angiogenesis during development and in the tumor environment. These studies should provide novel insights into how the de-SUMOylation pathway regulates the hypoxic response.

Public Health Relevance

We discovered a protein called SENP1 that can remove SUMO (Small Ubiquitin-like modifier) from SUMO- modified proteins. Deletion of SENP1 in mouse causes the embryo to die early due to severe anemia because SENP1 is required to maintain the stability of hypoxia-inducible factor 11 (HIF11) in the hypoxic environment. We will study how SENP1 is regulated by hypoxia, how HIF11 is modified by SUMO, and how SENP1 can regulate the development of normal and abnormal blood vessels.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA139520-04
Application #
8207903
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Snyderwine, Elizabeth G
Project Start
2009-03-01
Project End
2013-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
4
Fiscal Year
2012
Total Cost
$309,964
Indirect Cost
$108,689
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Lin, Feng-Ming; Yeh, Edward T H (2011) Balancing act during development: lessons from a SUMO-less SF-1. Dev Cell 21:191-2
Kang, Xunlei; Qi, Yitao; Zuo, Yong et al. (2010) SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell 38:191-201
Bawa-Khalfe, Tasneem; Yeh, Edward T H (2010) SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer 1:748-752
Bawa-Khalfe, Tasneem; Cheng, Jinke; Lin, Sue-Hwa et al. (2010) SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem 285:25859-66